Edition:
United States

Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

146.55USD
24 Nov 2017
Change (% chg)

$-0.49 (-0.33%)
Prev Close
$147.04
Open
$146.08
Day's High
$147.89
Day's Low
$146.08
Volume
159,630
Avg. Vol
582,596
52-wk High
$167.70
52-wk Low
$71.50

Chart for

About

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The... (more)

Overall

Beta: 1.61
Market Cap(Mil.): $37,062.91
Shares Outstanding(Mil.): 252.90
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.97 15.54
EPS (TTM): -- -- --
ROI: -- -10.87 11.80
ROE: -- -36.85 15.75

BRIEF-Vertex receives CHMP positive opinion for Orkambi for the treatment of children with cystic fibrosis ages 6-11

* Vertex receives CHMP positive opinion for Orkambi® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis ages 6-11 with two copies of the f508del mutation in the European Union Source text for Eikon: Further company coverage:

Nov 10 2017

Vertex ups cystic fibrosis sales view, but 2 trials fail

Vertex Pharmaceuticals Inc raised its outlook for full-year sales of its cystic fibrosis drugs as it released quarterly earnings on Wednesday, but the company reported disappointing results from two clinical trials and its shares tumbled 3 percent in after-hours trade.

Oct 25 2017

UPDATE 1-Vertex ups cystic fibrosis sales view, but 2 trials fail

Oct 25 Vertex Pharmaceuticals Inc raised its outlook for full-year sales of its cystic fibrosis drugs as it released quarterly earnings on Wednesday, but the company reported disappointing results from two clinical trials and its shares tumbled 3 percent in after-hours trade.

Oct 25 2017

Vertex posts wider net loss, raises cystic fibrosis sales outlook

Oct 25 Vertex Pharmaceuticals Inc reported a wider third-quarter net loss on Wednesday, on higher costs and onetime items, and raised its outlook for full-year sales of its key cystic fibrosis drugs.

Oct 25 2017

BRIEF-Vertex says FDA sets action date of Feb 28, 2018 for its Tezacaftor/Ivacaftor Combination Treatment

* Vertex announces acceptance of its applications for review of the tezacaftor/ivacaftor combination treatment in people with cystic fibrosis by the FDA and EMA

Aug 24 2017

BRIEF-FDA approves Kalydeco(Ivacaftor) for more than 600 people ages 2 and older with Cystic Fibrosis who have certain residual function mutations

* FDA approves Kalydeco (Ivacaftor) for more than 600 people ages 2 and older with Cystic Fibrosis who have certain residual function mutations

Aug 01 2017

BRIEF-Vertex interested in early stage assets consistent with CF focus

* Vertex says interested in acquiring early stage assets in disease areas consistent with cystic fibrosis

Jul 26 2017

Vertex Pharma's quarterly profit beats estimates

Vertex Pharmaceuticals Inc reported a better-than-expected profit for the third straight quarter, helped by improved sales of its cystic fibrosis (CF) drugs.

Jul 26 2017

UPDATE 1-Vertex Pharma's quarterly profit beats estimates

July 26 Vertex Pharmaceuticals Inc reported a better-than-expected profit for the third straight quarter, helped by improved sales of its cystic fibrosis (CF) drugs.

Jul 26 2017

Vertex Pharma reports quarterly profit

July 26 Vertex Pharmaceuticals Inc reported a quarterly profit, compared with a year-ago loss, helped by higher sales of its cystic fibrosis (CF) drugs.

Jul 26 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $138.01 +0.72
Pfizer Inc. (PFE.N) $35.51 +0.09
Novartis AG (NOVN.S) CHF83.40 -0.20
Merck & Co., Inc. (MRK.N) $54.35 -0.02
Roche Holding Ltd. (ROG.S) CHF246.50 -0.40
Roche Holding Ltd. (RO.S) CHF248.00 -0.20
Sanofi SA (SASY.PA) €77.45 -0.09
GlaxoSmithKline plc (GSK.L) 1,297.50 -8.00
AbbVie Inc (ABBV.N) $94.72 +0.25
Bristol-Myers Squibb Co (BMY.N) $61.43 +0.29

Earnings vs. Estimates